Calcium channel blockers (versus unexposed)

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17153
R71937		 Al Khalaf - Calcium channel blockers (Controls unexposed, disease free), 2022 Preeclampsia (based on read or ICD-10 codes) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, disease free excluded Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 8.15 [5.75;11.56] C
excluded (control group) 		36/289   29,859/1,739,944 29,895 289
ref
S17150
R71916		 Al Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022 Preeclampsia (based on read or ICD-10 codes) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 1.45 [1.04;2.02] C 43/289   839/7,809 882 289
ref
S13387
R52256		 Mito - Amlodipine, 2019 Superimposed preeclampsia at least 1st trimester retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 0.91 [0.45;1.85] C 15/48   43/129 58 48
ref
S13789
R54075		 Bayliss - Calcium blockers, 2002 Superimposed Pre-eclampsia (before and after 30 weeks) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 0.49 [0.13;1.83] C 3/14   61/171 64 14
ref
Total 3 studies 1.10 [0.66;1.83] 1,004 351
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Al Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022Al Khalaf - Calcium channel b..., 2022 1 1.45[1.04; 2.02]88228957%ROB confusion: criticalROB selection: unclearROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Mito - Amlodipine, 2019Mito - Amlodipine, 2019 0.91[0.45; 1.85]584831%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Bayliss - Calcium blockers, 2002Bayliss - Calcium blockers, 2002 0.49[0.13; 1.83]641413%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 42% 1.10[0.66; 1.83]1,0043510.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.10[0.66; 1.83]1,00435142%NAAl Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022 Mito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.10[0.66; 1.83]1,00435142%NAAl Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022 Mito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 3 Tags Adjustment   - No  - No 1.10[0.66; 1.83]1,00435142%NAAl Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022 Mito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 3 Indications Antihypertensive   - Only chronic hypertension indication  - Only chronic hypertension indication 1.10[0.66; 1.83]1,00435142%NAAl Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022 Mito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 3 All studiesAll studies 1.10[0.66; 1.83]1,00435142%NAAl Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022 Mito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 17153

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 8.15[5.75; 11.56]29,895289 -NAAl Khalaf - Calcium channel blockers (Controls unexposed, disease free), 2022 1 unexposed, sick controlsunexposed, sick controls 1.10[0.66; 1.83]1,00435142%NAAl Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022 Mito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 30.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Bellos - Amlodipine (Preeclampsia (Randomized ...Bellos - Amlodipine (Preeclampsia (Randomized controlled trial and Cohort studies)) 0.84[0.30; 2.33]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos - Nifedipine (Preeclampsia (Randomized ...Bellos - Nifedipine (Preeclampsia (Randomized controlled trial and Cohort studies)) 0.82[0.34; 3.88]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos - Amlodipine (Preeclampsia (Randomized ...Bellos - Amlodipine (Preeclampsia (Randomized controlled trial only)) 0.70[0.09; 5.45]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bellos - Nifedipine (Preeclampsia (Randomized ...Bellos - Nifedipine (Preeclampsia (Randomized controlled trial only)) 0.66[0.20; 2.16]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Abalos (Proteinuria/pre-eclampsia (RCT versus ...Abalos (Proteinuria/pre-eclampsia (RCT versus no antihypertensive drugs/placebo)) 1.40[1.02; 1.92]16%-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT4 Bone - GESTATIONAL HYPERTENSION (Severe hyper ...Bone - GESTATIONAL HYPERTENSION (Severe hypertension) 0.77[0.49; 1.19]23%-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 Bone - GESTATIONAL HYPERTENSION (Severe hyper ...Bone - GESTATIONAL HYPERTENSION (Severe hypertension (versus methyldopa)) Out of scale0.11[0.01; 0.99]32%-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 1.10[0.66; 1.83]42%351----Al Khalaf - Calcium channel blockers (Controls unexposed, sick), 2022 Mito - Amlodipine, 2019 Bayliss - Calcium blockers, 2002 30.510.01.0